Stabilized HIV-1 Env Trimers for Broad Neutralizing Antibody Elicitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing an HIV-1 vaccine that elicits broad and potent neutralizing antibodies is challenging due to the virus's immune evasion strategies and extreme sequence variability, making it difficult to generate antibodies that recognize conserved epitopes on the HIV envelope glycoprotein.
Innovation Solution
Engineering disulfide-stabilized SOSIP and flexibly linked NFL2P trimers derived from the subtype A BG505 Env, with specific mutations and disulfide linkages to lock gp120 in the native-trimer state, which better elicit antibodies and maintain native-like conformation, thereby enhancing trimer stability and antigenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HIV-1 envelope glycoprotein immunogens are used, then the vaccine can be manufactured, but the immunogens fail to maintain native-like trimer conformation and stability, resulting in inability to elicit broad neutralizing antibodies
Solution Approach 1:
The patent introduces specific point mutations (e.g., I559P in gp41) and engineered disulfide bonds (e.g., between residues 501C in gp120 and 605C in gp41) to alter the physical-chemical parameters of the envelope glycoprotein. These changes stabilize the trimeric conformation and prevent unwanted conformational transitions, thereby maintaining native-like structure while improving overall stability for vaccine application
Solution Approach 2:
The patent creates a composite structure by combining gp120 and gp41 subunits with engineered disulfide linkages to form a stabilized SOSIP trimer. This composite approach integrates the receptor-binding function of gp120 with the membrane fusion function of gp41, while the disulfide bonds provide structural reinforcement to maintain the native trimeric architecture
2Productivity
If existing soluble Env trimers are used, then they can be produced, but they undergo conformational changes upon CD4 binding that prevent effective antibody elicitation
Solution Approach 1:
The patent applies preliminary anti-action by introducing disulfide bonds and mutations that preemptively lock the envelope glycoprotein in its pre-fusion conformation. This prevents the conformational changes that would normally occur upon CD4 binding, thereby preserving the native trimer structure and enabling effective elicitation of broad neutralizing antibodies before the virus can change shape
3Reliability
If subtype B Envs are used for vaccine development, then they can be manufactured, but they exhibit poor trimer formation and stability compared to subtype A Envs
Solution Approach 1:
The patent applies parameter changes by introducing specific mutations known to enhance trimer stability (such as I559P in gp41) into subtype B Env sequences. These mutations compensate for the inherently poorer trimer formation propensity of subtype B Envs, enabling them to form stable, native-like trimers comparable to subtype A Envs while retaining subtype-specific antigenic properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered trimers improve trimer formation, stability, and antigenic profile, allowing for the elicitation of broad neutralizing antibodies that can effectively target the HIV envelope glycoprotein, addressing the limitations of existing vaccine immunogens.
Implementation Method 1
Engineering disulfide-stabilized SOSIP and flexibly linked NFL2P trimers derived from the subtype A BG505 Env, with specific mutations and disulfide linkages to lock gp120 in the native-trimer state
Data Source
AI summary
The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.